Can a GLP-1 change your periods in perimenopause?

Key takeaways

Dr. Linda's take

Women ask me this quietly, usually near the end of the visit. My cycle went strange after I started the medication. Is that the drug, or is that me getting older?

I love this question because it is so reasonable and the honest answer is so unsatisfying. Nobody has run the trial. What I can do is walk you through what we do know, tell you which part is solid enough to act on, and be clear about where the evidence simply stops. That is more useful than a confident guess.

Has anyone actually studied whether these medications change your period?

Not in perimenopausal women, as far as I can find. Searches for trials measuring menstrual bleeding as an outcome in this group come back empty.

That is worth sitting with, because absence of a study is not the same as absence of an effect. It means that if your cycle changed, no researcher has yet given you a proper basis for blaming the medication or clearing it. You are in genuinely uncharted territory, and you deserve to be told that rather than reassured falsely in either direction.

Is it perimenopause, or is it the medication?

Here is the confounder that makes this so hard: changing bleeding is how perimenopause is defined in the first place.

The STRAW+10 staging system, the international consensus for describing the menopause transition, stages the transition using bleeding criteria and recommends applying them regardless of a woman's age, ethnicity, body size, or lifestyle characteristics.

Read that last part again. Body size is explicitly not part of the staging. So a woman in her forties whose cycles turn irregular has a powerful competing explanation sitting right there, one that has nothing to do with any medication. If you started something new around the same time, the two are almost impossible to separate in a single person. For the hormone-therapy side of this question, see can you use a GLP-1 and hormone therapy together in perimenopause.

Is there a way a GLP-1 could affect cycles indirectly?

Yes, and this part rests on much firmer ground. It runs through weight and ovulation rather than through the drug acting on your uterus.

Obese women undergo perturbations of the hypothalamic-pituitary-ovarian axis and frequently suffer menstrual dysfunction leading to anovulation and infertility. That is the axis that runs your cycle. When body weight changes, that signaling can change with it.

And weight loss itself, however it is achieved, can move cycles measurably. In women with PCOS and excess weight, weight loss of more than 5% of pretreatment weight restored menstrual regularity in 89%, of whom 30% achieved spontaneous pregnancy.

Two honest caveats you should hold onto. That research was in women with PCOS, not perimenopausal women, so the 89% is not your number. And that weight loss came from diet and exercise, not from medication. What it establishes is the principle: change the weight, and cycles can follow. It does not establish that a medication does it.

The closest thing to direct evidence comes from a six-month study of 96 women with excess weight and irregular, anovulatory cycles, in which ovulatory cycles were observed in 52.5% of previously anovulatory women following semaglutide treatment. Treat that gently. It had no control group, so there is no way to separate a drug effect from a weight-loss effect, and the population was a PCOS-type group rather than women in perimenopause.

Do these medications work differently in perimenopause?

For weight, there is real data, and it is unusually specific.

A post hoc analysis of the SURMOUNT trials looked at women by reproductive stage and found that in SURMOUNT-1, significantly greater body weight reductions were observed with tirzepatide versus placebo in women in perimenopause, at 23% versus 3%.

That is a genuinely useful finding, because perimenopausal women are so often told their bodies simply will not respond. We look at the body-composition side in does a GLP-1 cause muscle loss in perimenopause. But notice precisely what it measured: body weight. It says nothing at all about periods. I am flagging that because this is exactly the citation that tends to drift in the retelling.

What about my birth control?

This is the part I most want you to take away, because it is concrete, it is on the label, and it is actionable.

The two medications differ, and that surprises people who assume they are interchangeable.

For tirzepatide, the label states that use may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, that this delay is largest after the first dose and diminishes over time, and it advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. The label also notes that hormonal contraceptives that are not administered orally should not be affected.

The underlying pharmacology is striking. Following a combined oral contraceptive with a single 5 mg dose of tirzepatide, mean peak concentrations of ethinyl estradiol, norgestimate, and norelgestromin were reduced by 59%, 66%, and 55%, while mean total exposure was reduced by 20%, 21%, and 23%. The peak drop is large, the overall exposure drop is more modest, and that is precisely why the warning is tied to starting and to each dose increase rather than to forever.

Semaglutide is a different story. No clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel were observed when used together with semaglutide. An independent trial in 43 women found that semaglutide did not reduce the bioavailability of ethinylestradiol and levonorgestrel. One caveat for accuracy: those participants were postmenopausal women with type 2 diabetes taking a 1.0 mg dose, so this is reassuring rather than a perfect match for a perimenopausal woman on a higher weight-management dose.

Could I get pregnant when I did not expect to?

This is the part that catches women in their forties off guard. Many assume that irregular cycles mean fertility has already gone. Perimenopause means ovulation is unpredictable, not that it has stopped.

Now layer on what is above: weight loss can restore ovulation, and if you are on tirzepatide and taking a pill, the label itself says the pill may be working less well right when that is happening. Those two facts point the same direction at the same moment.

If pregnancy is not what you want, that is a conversation to have before you start, not after.

What should I ask my clinician?

General education, not a plan for you. Fair questions to raise:

If you want to know whether one of these medications is a reasonable fit for you at all, start with our eligibility quiz.

One thing that is not negotiable: bleeding that is heavy, prolonged, between periods, or after a year with no periods deserves evaluation in its own right. It should never be waved away as a side effect of a medication, by you or anyone else.

The honest bottom line

Can a GLP-1 change your periods in perimenopause? Directly, nobody has shown that, because nobody has run the study. Indirectly, through weight and ovulation, there is a plausible and reasonably well-documented path, and the clearest, most actionable piece is on the tirzepatide label about oral contraceptives.

Perimenopause is already a season of being told that whatever you are noticing is probably nothing. I would rather hand you the map with the blank spaces honestly marked than pretend the whole thing is filled in.

Frequently asked questions

Has any trial shown that a GLP-1 changes menstrual bleeding in perimenopause?

No trial has been designed to measure menstrual bleeding as an outcome in perimenopausal women taking these medications. That is an absence of study, not proof of an absence of effect.

Could a GLP-1 affect my cycle indirectly?

Plausibly, through weight and ovulation. Obese women undergo perturbations of the hypothalamic-pituitary-ovarian axis and frequently suffer menstrual dysfunction leading to anovulation and infertility, and weight loss can move cycles. In women with PCOS and excess weight, weight loss of more than 5% of pretreatment weight restored menstrual regularity in 89%, of whom 30% achieved spontaneous pregnancy. That research was in PCOS, not perimenopause.

Does tirzepatide affect birth control pills?

Yes, according to its label. Use of tirzepatide may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. The label also notes that hormonal contraceptives that are not administered orally should not be affected.

Does semaglutide affect birth control pills the same way?

No. No clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel were observed when used together with semaglutide, and an independent trial in 43 women found that semaglutide did not reduce the bioavailability of ethinylestradiol and levonorgestrel.

Do these medications still work in perimenopause?

For weight, yes. A post hoc analysis of the SURMOUNT trials found that in SURMOUNT-1, significantly greater body weight reductions were observed with tirzepatide versus placebo in women in perimenopause, at 23% versus 3%. That analysis measured weight, not periods.

When should bleeding changes be checked out?

Bleeding that is heavy, prolonged, between periods, or after a year with no periods deserves evaluation in its own right, regardless of any medication. This article is general education, so bring that to a clinician rather than assuming it is a side effect.

References

1. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-17).
2. The Journal of clinical endocrinology and metabolism (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. PubMed PMID 22344196. https://pubmed.ncbi.nlm.nih.gov/22344196/ (Accessed 2026-07-17).
3. Reproductive biology and endocrinology : RB&E (2018). Obesity as disruptor of the female fertility. PubMed PMID 29523133. https://pubmed.ncbi.nlm.nih.gov/29523133/ (Accessed 2026-07-17).
4. Acta obstetricia et gynecologica Scandinavica (2004). Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. PubMed PMID 15225184. https://pubmed.ncbi.nlm.nih.gov/15225184/ (Accessed 2026-07-17).
5. Journal of clinical medicine (2026). Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. PubMed PMID 42452625. https://pubmed.ncbi.nlm.nih.gov/42452625/ (Accessed 2026-07-17).
6. Obesity (Silver Spring, Md.) (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. PubMed PMID 40074721. https://pubmed.ncbi.nlm.nih.gov/40074721/ (Accessed 2026-07-17).
7. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-17).
8. Journal of clinical pharmacology (2015). Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. PubMed PMID 25475122. https://pubmed.ncbi.nlm.nih.gov/25475122/ (Accessed 2026-07-17).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-17.*